Enhanc3D Genomics is a functional genomics company exploring the 3D organisation of DNA in health and disease. The company leverages its GenLink3D platform to identify new biomarkers and novel treatment targets for cancer, ageing, and autoimmune conditions.

Enhanc3D Genomics

CSM provides tools for converting images, text, or sketches into 3D models and environments. The service aims to accelerate 3D production workflows, reducing the time and cost associated with creating 3D assets.

Sloyd is an AI-driven design platform that enables users to create and customize 3D models for various applications, including gaming, VR, and AR. The platform leverages machine learning to simplify the design process, making it accessible to both professionals and hobbyists.

Sloyd

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Metric
Company Name	Enhanc3D Genomics	CSM	Sloyd	Agilent Technologies, Inc.
Symbol				A
MSH ID	COM:ENHANC3DGENOMICS	AI:CSM	AI:SLOYD	COM:AGILENT
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Technology	Technology	Healthcare
Industry	Biotechnology	Software Development	Technology	Medical - Diagnostics & Research
Country	GB	US	NO	US
Stage
Employee Count			15	17.60K
Website	enhanc3dgenomics.com	csm.ai	sloyd.ai	agilent.com
LinkedIn			sloyd
Founders

Metric
Market Cap				37.07B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue				6.51B
Revenue (LTM)
Revenue (NTM)
Gross Profit				6.51B
EBITDA				1.49B
Operating Income				1.49B
Net Income				1.29B
EPS				4.44
Diluted EPS				4.43
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.55
Operating Profit Margin				0.23
EBITDA Margin				0.23
Net Profit Margin				0.22
Return on Equity				0.23
Return on Assets				0.13
Return on Capital Employed				0.17

COM:ENHANC3DGENOMICS

Enhanc3D Genomics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				31.39
P/B Ratio				6.66
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				6.74
EV Multiple				26.83

Metric
Days Sales Outstanding				68.96
Days Payables Outstanding				45.30
Days Inventory Outstanding				121.71
Operating Cycle				190.64
Cash Conversion Cycle				130.21
Asset Turnover				0.62

Metric
Operating Cash Flow				1.77B
Free Cash Flow				1.47B
Cash Flow to Debt				0.77
Operating Cash Flow/Sales				0.30
Free Cash Flow Yield				0.04

Metric
Cash & Equivalents				1.59B
Accounts Receivable				132M
Inventory				1.03B
Goodwill				3.96B
Debt to Capitalization				0.33
Debt to Assets				0.25
Current Ratio				2.61
Quick Ratio				1.88

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.02
R&D to Revenue				0.07
SG&A to Revenue